Ascelia

Ascelia Pharma is a biotech company focused on orphan oncology treatments, headquartered in Malmo, Sweden, and listed on Nasdaq Stockholm under the ticker ACE. The company develops and commercializes novel drugs that address unmet medical needs with a clear development and market pathway, and currently has two drug candidates in clinical development: Orviglance, an FDA Orphan Drug-designated oral contrast agent for MRI imaging of liver lesions in patients with reduced kidney function, and Oncoral, an oral irinotecan tablet being developed as an alternative to intravenous chemotherapy for gastric cancer.